Ibrutinib was the first drug that was approved by the US Food and Drug Administration (FDA) specifically for Waldenstrom’s macroglobulinemia (WM). In the past couple of years there has been an explosion of research on ibrutinib of special interest to patients with WM and their caregivers. This newly revised IWMF Ibrutinib Fact Sheet introduces the interested reader to updates on the targeted therapy. New information is provided on dosing, side effects, and useful self-care tips. The updated fact sheet is available in English, Chinese (both Simplified and Traditional), French, German, Italian, Spanish, and Norwegian. They all can be downloaded at www.iwmf.com/library/iwmf-and-affiliate-publications.
Presenting the 2018 Revised IWMF Ibrutinib Fact Sheet
12 Jul, 2018